Hussman Strategic Advisors’s TG Therapeutics TGTX Stock Holding History

Hussman Strategic Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.88M	Buy	+52,500	New	+$2.15M	0.66%	48
2025 Q4	–	Sell	-126,000	Closed	-$4.55M	–	354
2025 Q3	$4.55M	Hold	126,000	–	–	0.99%	5
2025 Q2	$4.53M	Buy	126,000 +73,500	+140%	+$2.74M	1.04%	12
2025 Q1	$2.07M	Buy	52,500 +10,500	+25%	+$353K	0.5%	78
2024 Q4	$1.26M	Sell	42,000 -63,000	-60%	-$1.81M	0.37%	113
2024 Q3	$2.46M	Buy	+105,000	New	+$2.29M	0.6%	60
2023 Q4	–	Sell	-52,500	Closed	-$439K	–	295
2023 Q3	$439K	Buy	+52,500	New	+$732K	0.08%	245

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Hussman Strategic Advisors's TGTX Position: Q2 2026 in Review

Hussman Strategic Advisors opened a new position in TG Therapeutics (TGTX) in Q2 2026: 52,500 shares worth $2.88M. The stake represents 0.66% of the portfolio and ranks #48 among its holdings. This is a return to the name: Hussman Strategic Advisors previously reported a position in TGTX as recently as Q3 2025.

Hussman Strategic Advisors first reported a position in TGTX in Q3 2023 and has held it in 7 quarters since. The position peaked at $4.55M in Q3 2025. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Hussman Strategic Advisors held 52,500 shares of TG Therapeutics worth $2.88M as of Q2 2026.
TG Therapeutics was a new Hussman Strategic Advisors position in Q2 2026.
TG Therapeutics made up 0.66% of Hussman Strategic Advisors's portfolio in Q2 2026, its #48 holding.
Hussman Strategic Advisors first reported a position in TG Therapeutics in Q3 2023 and has held it in 7 quarters since.
Hussman Strategic Advisors's TG Therapeutics position peaked at $4.55M in Q3 2025.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.